Regeneron's experimental therapy combo effective in untreated cancer patients
06.12.2025
Dec 6 () - Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first part of a late-stage trial. The trial, which enrolled 22 patients, studied safety and preliminary efficacy of the company's therapy, odronextamab, in combination with chemotherapy in patients with Diffuse Large B-Cell Lymphoma or DLBCL.